US Patent

US10543179 — Dosage regimen of an S1P receptor modulator

Method of Use · Assigned to Novartis Pharmaceuticals Corp · Expires 2027-12-25 · 2y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a dosage regimen of fingolimod or a pharmaceutically acceptable salt thereof, administered at a daily dosage of 0.5 mg, preceded by vaccination and infection testing.

USPTO Abstract

The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2719 — fingolimod-hydrochloride

Patent Metadata

Patent number
US10543179
Jurisdiction
US
Classification
Method of Use
Expires
2027-12-25
Drug substance claim
No
Drug product claim
No
Assignee
Novartis Pharmaceuticals Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.